When it was named in a patent-infringement suit filed by Benitec, Nucleonics declined to go the way of its co-defendants and settle the matter with a license to Benitec’s DNA-directed RNAi technology.

Instead, Nucleonics decided to fight and began launching attacks of its own. Now it appears that the company’s strategy is about to start paying off: Following a review of two Benitec patents made at the behest of Nucleonics, the Australian patent office (known as IP Australia) is poised to begin proceedings that could result in the revocation of the patents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.